AI assistant
Sending…
LIGAND PHARMACEUTICALS INC — Director's Dealing 2014
Mar 20, 2014
31289_dirs_2014-03-20_9533cf4a-4c6e-4875-8dc4-765679fa7c6c.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: LIGAND PHARMACEUTICALS INC (LGND)
CIK: 0000886163
Period of Report: 2014-03-18
Reporting Person: LAMATTINA JOHN L (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2014-03-18 | Common Stock | M | 5000.0 | $8.97 | Acquired | 26356 | Direct |
| 2014-03-18 | Common Stock | S | 5000.0 | $78.83 | Disposed | 21356 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2014-03-18 | Non-Qualified Stock Option (right to buy) | $8.97 | M | 5000.0 | Disposed | 2014-02-07 | Common Stock (5000) | Direct |
Footnotes
F1: The option becomes exercisable in 36 successive equal monthly installments upon completion of each calendar month of service beginning on the grant date.
More from LIGAND PHARMACEUTICALS INC
Proxy Solicitation & Information Statement
2026
May 18
M&A Activity
2026
May 18
Interim / Quarterly Report
2026
May 8
Earnings Release
2026
May 7
Major Shareholding Notification
2026
May 1
Major Shareholding Notification
2026
May 1
Regulatory Filings
2026
Apr 30
Proxy Solicitation & Information Statement
2026
Apr 27
M&A Activity
2026
Apr 27
Annual Report
2026
Apr 21